Original news and analysis on international IP policy
Gaudenz Silberschmidt, head of international affairs in Switzerland's public health office for the past decade, has been nominated to become senior adviser in the World Health Organization Office of the Director-General. He will have a special focus on the reform process taking place at the cash-strapped UN agency.
The director of the World Health Organization, the global public health body, today vigorously applauded the ruling by Australia's high court upholding the Australian government's upcoming ban on trademarked labels on tobacco packages. The case pits international trade interests against public health interests, and the WHO said it hopes today's ruling will have a "domino effect" for many other countries considering such bans.
The international pharmaceutical industry this week released a policy statement targeting counterfeit medicines on the internet. Among the recommendations was for the Internet Corporation for Assigned Names and Numbers (ICANN) to join the fight.
World Health Organization Director General Margaret Chan was re-elected for another term at the annual May World Health Assembly. Now the WHO has issued a "report card" showing how she kept her promises during the first term. This includes a range of steps to ensure new drugs are affordable and accessible, even if intellectual property rights make them high-priced.
The accessibility and affordability of drugs in developing countries depend on robust generic competition and would benefit from greater transparency in the terms and conditions of licensing agreements, the acting head of the Medicines Patent Pool said on a panel at the World Intellectual Property Organization that included a speaker from the Indian generics industry and a representative of Gilead Sciences.
A new pharmaceutical industry initiative aimed at improving access to HIV treatments in least-developed countries is raising questions as to how it will fit with the Medicines Patent Pool, an existing group with a similar mandate. As an informal meeting on the new initiative kicks off this week in New Delhi, scrutiny will be paid to whether the initiative’s drivers are several companies that have declined to negotiate with the patent pool and whether it is a good-faith effort to help the greatest number of patients.
The World Health Organization has published a paper that explains to policymakers and others how to take measures to protect public health against tobacco while staying within the bounds of international trade and investment law, under intense industry pressure. Key aspects of the report deal with intellectual property rights policy, as it relates to international trade.
The shadow of the tobacco industry was present at last week’s annual World Health Assembly, featuring the villain in what World Health Organization Director General Margaret Chan called a theatre of the absurd. The tactics of the "evil industry," as she called it, aimed at undermining countries' efforts to implement tobacco control legislations were illustrated with concrete country examples at a side event during the week.
With a generous pledge and a grand vision, Bill Gates launched the “Decade of Vaccines” two years ago. By endorsing a “Global Vaccine Action Plan” during the World Health Assembly, the world’s health authority stands as the lead agency in advancing the initiative.
One year since the adoption of the Pandemic Influenza Preparedness Framework, member states emphasised the importance of bio-sharing initiative and in some in cases raised concerns about the pace of implementation.
World Health Organization member states have decided to establish a new mechanism for international collaboration to prevent and control “substandard, spurious, falsely-labelled, falsified and counterfeit medical products” (SSFFC). Excluding trade and intellectual property considerations, this mechanism is called to approach the problem strictly from a public health perspective.
A proposal at this week’s World Health Assembly to negotiate a binding convention on research and development for neglected diseases - those predominantly afflicting poor populations - ran into resistance from developed countries which hold the view that another approach might be possible. But an agreement was reached on a way forward for the expert report that recommended the binding convention.